Protocol Ledger

NCT04632940 · Phase III · TERMINATED

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Interventional Phase III clinical trial protocol NCT04632940 sponsored by Kyntra Bio in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-03 Enrollment: 73 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04632940
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)73 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04632940
Protocol FieldVerified Registry Value
NCT IdentifierNCT04632940
Consolidated Lead SponsorKyntra Bio
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment73 participants (ACTUAL)
Registered Start Date2021-03-03
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI